CL2020002663A1 - Compuestos moduladores alostéricos positivos gabaa, métodos de preparación y usos de los mismos - Google Patents
Compuestos moduladores alostéricos positivos gabaa, métodos de preparación y usos de los mismosInfo
- Publication number
- CL2020002663A1 CL2020002663A1 CL2020002663A CL2020002663A CL2020002663A1 CL 2020002663 A1 CL2020002663 A1 CL 2020002663A1 CL 2020002663 A CL2020002663 A CL 2020002663A CL 2020002663 A CL2020002663 A CL 2020002663A CL 2020002663 A1 CL2020002663 A1 CL 2020002663A1
- Authority
- CL
- Chile
- Prior art keywords
- preparation methods
- positive allosteric
- allosteric modulator
- modulator compounds
- gabaa positive
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
En el presente documento se describen polimorfos que comprenden 2’,6-difluoro-5’-[3-(1-hidroxi-1-metiletil)-imidazo[1,2-b][1,2,4] triazin-7-il]bifenil-2-carbonitrilo (TPA023B) o sales del mismo. En un aspecto del presente documento se describe una sal polimórfica cristalina o cocristal de TPA023B con ácido fosfórico. En el presente documento también se describen métodos de preparación y uso de los mismos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862659226P | 2018-04-18 | 2018-04-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020002663A1 true CL2020002663A1 (es) | 2021-06-11 |
Family
ID=68239798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020002663A CL2020002663A1 (es) | 2018-04-18 | 2020-10-15 | Compuestos moduladores alostéricos positivos gabaa, métodos de preparación y usos de los mismos |
Country Status (14)
Country | Link |
---|---|
US (2) | US11542263B2 (es) |
EP (1) | EP3781566A4 (es) |
JP (2) | JP7449272B2 (es) |
KR (1) | KR20210011921A (es) |
CN (1) | CN112384513A (es) |
AU (1) | AU2019255282B2 (es) |
BR (1) | BR112020021104A2 (es) |
CA (1) | CA3096890A1 (es) |
CL (1) | CL2020002663A1 (es) |
IL (1) | IL278067A (es) |
MX (2) | MX2020010878A (es) |
SG (1) | SG11202010220QA (es) |
TW (1) | TW202012402A (es) |
WO (1) | WO2019204446A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3096890A1 (en) * | 2018-04-18 | 2019-10-24 | Neurocycle Therapeutics, Inc. | Gabaa positive allosteric modulator compounds, methods of making, and uses thereof |
CN113840610A (zh) * | 2019-03-18 | 2021-12-24 | 纽罗塞克医疗公司 | Gabaa受体调节剂用于治疗疼痛的用途 |
CN114981266A (zh) * | 2019-10-22 | 2022-08-30 | 纽罗塞克医疗公司 | Gabaa正向变构调节剂化合物、其制备方法和用途 |
MX2022004945A (es) * | 2019-10-23 | 2022-08-04 | Neurocycle Therapeutics Inc | Tratamiento de afecciones epilépticas con moduladores del receptor gabaa. |
US20210401849A1 (en) * | 2020-06-30 | 2021-12-30 | University Of Mississippi Medical Center | Methods for treating benzodiazepine misuse/use disorder |
WO2024076999A2 (en) * | 2022-10-04 | 2024-04-11 | Engrail Therapeutics, Inc. | Gabaa receptor modulators and uses thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9813576D0 (en) | 1998-06-24 | 1998-08-19 | Merck Sharp & Dohme | Therapeutic agents |
EP1343788B1 (en) * | 2000-11-10 | 2005-11-23 | MERCK SHARP & DOHME LTD. | Imidazo-triazine derivatives as ligands for gaba receptors |
GB0117277D0 (en) | 2001-07-16 | 2001-09-05 | Merck Sharp & Dohme | Therapeutic agents |
TWI248936B (en) | 2001-03-21 | 2006-02-11 | Merck Sharp & Dohme | Imidazo-pyrimidine derivatives as ligands for GABA receptors |
CA2724742C (en) | 2008-05-21 | 2016-07-19 | Incyte Corporation | Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
US20110082147A1 (en) * | 2009-07-24 | 2011-04-07 | Concert Pharmaceuticals, Inc. | Substituted imidazotriazines |
EP3407886A1 (en) * | 2016-01-27 | 2018-12-05 | Universität Zürich | Use of gabaa receptor modulators for treatment of itch |
CA3096890A1 (en) * | 2018-04-18 | 2019-10-24 | Neurocycle Therapeutics, Inc. | Gabaa positive allosteric modulator compounds, methods of making, and uses thereof |
-
2019
- 2019-04-17 CA CA3096890A patent/CA3096890A1/en active Pending
- 2019-04-17 TW TW108113441A patent/TW202012402A/zh unknown
- 2019-04-17 AU AU2019255282A patent/AU2019255282B2/en active Active
- 2019-04-17 BR BR112020021104-4A patent/BR112020021104A2/pt unknown
- 2019-04-17 JP JP2021506619A patent/JP7449272B2/ja active Active
- 2019-04-17 EP EP19788410.9A patent/EP3781566A4/en active Pending
- 2019-04-17 MX MX2020010878A patent/MX2020010878A/es unknown
- 2019-04-17 KR KR1020207033073A patent/KR20210011921A/ko not_active Application Discontinuation
- 2019-04-17 WO PCT/US2019/027880 patent/WO2019204446A1/en active Application Filing
- 2019-04-17 SG SG11202010220QA patent/SG11202010220QA/en unknown
- 2019-04-17 CN CN201980041321.7A patent/CN112384513A/zh active Pending
-
2020
- 2020-10-14 MX MX2024004400A patent/MX2024004400A/es unknown
- 2020-10-15 IL IL278067A patent/IL278067A/en unknown
- 2020-10-15 CL CL2020002663A patent/CL2020002663A1/es unknown
- 2020-10-16 US US17/072,282 patent/US11542263B2/en active Active
-
2022
- 2022-12-28 US US18/089,661 patent/US20230139418A1/en active Pending
-
2024
- 2024-02-29 JP JP2024030150A patent/JP2024063136A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2019204446A1 (en) | 2019-10-24 |
JP2024063136A (ja) | 2024-05-10 |
US11542263B2 (en) | 2023-01-03 |
AU2019255282B2 (en) | 2024-08-08 |
EP3781566A1 (en) | 2021-02-24 |
CA3096890A1 (en) | 2019-10-24 |
KR20210011921A (ko) | 2021-02-02 |
US20210040103A1 (en) | 2021-02-11 |
MX2020010878A (es) | 2021-01-29 |
AU2019255282A1 (en) | 2020-11-05 |
MX2024004400A (es) | 2024-04-29 |
JP2021522330A (ja) | 2021-08-30 |
TW202012402A (zh) | 2020-04-01 |
IL278067A (en) | 2020-11-30 |
EP3781566A4 (en) | 2022-06-22 |
JP7449272B2 (ja) | 2024-03-13 |
BR112020021104A2 (pt) | 2021-02-23 |
US20230139418A1 (en) | 2023-05-04 |
SG11202010220QA (en) | 2020-11-27 |
CN112384513A (zh) | 2021-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020002663A1 (es) | Compuestos moduladores alostéricos positivos gabaa, métodos de preparación y usos de los mismos | |
CL2020002848A1 (es) | Sales de un inhibidor de fgfr. | |
ECSP20070854A (es) | Compuestos heteroaril tetracíclicos | |
CU24605B1 (es) | Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2 | |
CL2020002839A1 (es) | Formas sólidas de un inhibidor de fgfr y procesos para prepararlas. | |
CO2018013978A2 (es) | Derivados de ácido borónico y usos terapéuticos de los mismos. | |
SV2016005312A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cã�ncer | |
CO2018003969A2 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona | |
DOP2018000115A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
NI201800058A (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer. | |
DOP2018000065A (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer | |
CL2020002530A1 (es) | Ciano tienotriazolpirazinas y usos de las mismas.(divisional de solicitud 621-2018) | |
GT201300207A (es) | Derivados de heteroarilo como moduladores de nachr alfa 7 | |
CO2018014339A2 (es) | Formas sólidas cristalinas de un inhibidor de bet | |
ECSP20029142A (es) | Ligandos de psma para la formación de imágenes y endorradioterapia | |
AR108461A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
DOP2016000308A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
CL2017000223A1 (es) | [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas | |
DOP2019000228A (es) | COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER | |
CO2021013166A2 (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria | |
CL2018000391A1 (es) | Combinaciones farmacéuticas y su uso | |
CL2022000980A1 (es) | Compuestos moduladores alostéricos positivos de gabaa, métodos de preparación y usos de los mismos | |
MX2020003832A (es) | Compuestos heteroarilos como moduladores alostericos positivos del receptor muscarinico m1. | |
BR112021018357A2 (pt) | Forma cristalina de inibidor de fosfodiesterase, método de preparação para a mesma e uso da mesma |